Celebrating a Year of Growth and Research

As 2025 draws to a close, Dermatology Times reflects on another year defined by innovation, collaboration, and progress across the specialty. From groundbreaking approvals and new therapeutic targets to evolving practice models and patient-centered care strategies, this year has demonstrated dermatology’s remarkable adaptability and forward momentum. In this issue, we take a moment to celebrate the clinicians who continue to shape dermatology. 

This month’s cover collection addresses the numerous therapeutics advancements in 2025, beginning with an in-depth look at atopic dermatitis (AD) and psoriasis by Joshua Burshtein, MD. In his review, Burshtein discussed new data on dupilumab and lebrikizumab for moderate to severe AD, 2.5-year safety and efficacy data for upadacitinib, and more. In psoriasis, positive 4-year data for bimekizumab in difficult-to-treat psoriasis sites, guselkumab for pediatric psoriasis and psoriatic arthritis, and more.

As part of the cover collection, the Dermatology Times staff created a timeline of key 2025 approvals, including roflumilast foam for plaque psoriasis, remibrutinib for chronic spontaneous urticaria, and more. With 2026 right around the corner, we also included a glimpse at research to watch for next year, including amlitelimab for atopic dermatitis, upadacitinib for alopecia areata, sonelokimab for hidradenitis suppurativa, and more.

Other major highlights from this issue include a look into Mohs surgery as the gold standard for nonmelanoma skin cancers, especially related to former President Biden’s recent basal cell carcinoma diagnosis and removal. Author and Mohs surgeon Nicole A. Negbenebor, MD, offered her insights into the clinical benefits of Mohs surgery for patients.

Jennifer Lightowler, MMSc, PA-C, highlighted the role of a dual IL-17A and IL-36R blockade with secukinumab and recibokibart for hidradenitis suppurativa. According to the case report, by addressing multiple inflammatory mechanisms simultaneously, such regimens may achieve deeper, more durable remission.

As always, Dermatology Times delivers the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert perspectives. Stay informed with the latest data—subscribe to Dermatology Times’ e-newsletters and follow us on Facebook, LinkedIn, and X.

With the upcoming start of the new year, Dermatology Times welcomes clinicians to submit clinical, original manuscripts for publication consideration to DTEditor@mmhgroup.com.

Mike Hennessy Jr
Chairman and CEO
MJH Life Sciences